BRPI0519759A2 - composiÇÕes farmacÊuticas - Google Patents
composiÇÕes farmacÊuticasInfo
- Publication number
- BRPI0519759A2 BRPI0519759A2 BRPI0519759-7A BRPI0519759A BRPI0519759A2 BR PI0519759 A2 BRPI0519759 A2 BR PI0519759A2 BR PI0519759 A BRPI0519759 A BR PI0519759A BR PI0519759 A2 BRPI0519759 A2 BR PI0519759A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- compounds
- kinase
- group
- gsk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
COMPOSIÇÕES FARMACÊUTICAS. A invenção fornece um composto da fórmula (I): ou um sal, solvato, tautômero ou N-óxido deste, em que M é selecionado de um grupo D1 e um grupo D2: em que R¹, E, A e X são tais como definidos nas reivindicações. São também fornecidas composições farmacêuticas que contêm os compostos, processos para a produção dos compostos e o emprego dos compostos na profilaxia ou tratamento de um estado de doença mediado por uma cinase CDK, cinase GSK-3 ou Aurora cinase.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64059704P | 2004-12-30 | 2004-12-30 | |
US64047504P | 2004-12-30 | 2004-12-30 | |
GB0428554A GB0428554D0 (en) | 2004-12-30 | 2004-12-30 | Pharmaceutical compounds |
GB0428552A GB0428552D0 (en) | 2004-12-30 | 2004-12-30 | Pharmaceutical compounds |
PCT/GB2005/005097 WO2006070195A1 (en) | 2004-12-30 | 2005-12-30 | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0519759A2 true BRPI0519759A2 (pt) | 2009-03-10 |
Family
ID=39495737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0519759-7A BRPI0519759A2 (pt) | 2004-12-30 | 2005-12-30 | composiÇÕes farmacÊuticas |
Country Status (14)
Country | Link |
---|---|
US (2) | US8110573B2 (pt) |
EP (2) | EP1833819A1 (pt) |
JP (1) | JP5507049B2 (pt) |
KR (1) | KR101334511B1 (pt) |
AU (1) | AU2005321091B2 (pt) |
BR (1) | BRPI0519759A2 (pt) |
CA (1) | CA2593993C (pt) |
IL (1) | IL183751A0 (pt) |
MX (1) | MX2007008008A (pt) |
NO (1) | NO20073926L (pt) |
NZ (1) | NZ555982A (pt) |
RU (1) | RU2416610C2 (pt) |
TW (1) | TWI427077B (pt) |
WO (1) | WO2006070195A1 (pt) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
EP1833819A1 (en) | 2004-12-30 | 2007-09-19 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
JP2008526721A (ja) * | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Cdk、gsk及びオーロラキナーゼの活性を調節するチアゾールおよびイソチアゾール誘導体 |
PL1877379T3 (pl) | 2005-04-13 | 2013-06-28 | Astex Therapeutics Ltd | Pochodne hydroksybenzamidu i ich wykorzystanie, jako inhibitorów hsp90 |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP5474354B2 (ja) * | 2005-12-30 | 2014-04-16 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
SA07280004B1 (ar) | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
EP1998777A1 (en) * | 2006-03-20 | 2008-12-10 | F. Hoffmann-La Roche AG | Methods of inhibiting btk and syk protein kinases |
WO2008001101A2 (en) * | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2049119A2 (en) * | 2006-06-29 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea |
WO2008041767A1 (fr) * | 2006-10-05 | 2008-04-10 | Banyu Pharmaceutical Co., Ltd. | Marqueur de gène ou de protéine utilisé pour la prévision ou le diagnostic de l'efficacité pharmacologique d'un inhibiteur d'aurora a |
SG175609A1 (en) | 2006-10-09 | 2011-11-28 | Takeda Pharmaceutical | Kinase inhibitors |
WO2008044054A2 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in therapy |
GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
US8883790B2 (en) * | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
WO2009138799A1 (en) * | 2008-05-14 | 2009-11-19 | Astex Therapeutics Limited | Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea |
US20100273808A1 (en) * | 2008-11-21 | 2010-10-28 | Millennium Pharmaceticals, Inc. | Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders |
ES2468391T3 (es) | 2008-12-22 | 2014-06-16 | Millennium Pharmaceuticals, Inc. | Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20 |
JP5872539B2 (ja) * | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドホスホルアミダート |
US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
PE20140913A1 (es) | 2010-11-15 | 2014-08-22 | Abbvie Inc | Inhibidores de nampt y rock |
MX341504B (es) | 2011-09-14 | 2016-08-19 | Samumed Llc | Indazol-3-carboxamidas y su uso como inhibidores de la trayectoria de señalización de wnt/b-catenina. |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
BR112014024284B1 (pt) | 2012-05-04 | 2021-08-31 | Samumed, Llc | Compostos de 1h-pirazolo[3,4-b]piridinas, composição farmacêutica compreendendo ditos compostos e usos terapêuticos destes |
PL403149A1 (pl) | 2013-03-14 | 2014-09-15 | Celon Pharma Spółka Akcyjna | Nowe związki pochodne pirazolilobenzo[d]imidazolu |
AU2014337356B2 (en) | 2013-10-15 | 2018-04-19 | Radux Devices, LLC | Securing a medical device to a valve instrument |
KR102078853B1 (ko) | 2013-11-27 | 2020-02-18 | 삼성전자 주식회사 | 메모리 시스템, 호스트 시스템 및 메모리 시스템에서의 라이트 동작 수행 방법 |
WO2015085289A1 (en) | 2013-12-06 | 2015-06-11 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
CA2978170C (en) | 2015-03-09 | 2024-02-27 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
MX2017015521A (es) * | 2015-06-04 | 2018-11-09 | Aurigene Discovery Tech Ltd | Derivados de heterociclilos sustituidos como inhibidores de cdk. |
PL3310331T3 (pl) * | 2015-06-17 | 2021-04-19 | Nabriva Therapeutics GmbH | Farmaceutyczne formulacje lefamuliny do iniekcji |
WO2017023996A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023975A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
AU2016348639B2 (en) | 2015-11-06 | 2022-09-08 | Samumed, Llc | Treatment of osteoarthritis |
MD3464285T2 (ro) | 2016-06-01 | 2023-01-31 | Biosplice Therapeutics Inc | Procedeu pentru prepararea N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)piridin-3-il)-3-metilbutanamidei |
KR102593742B1 (ko) | 2016-10-21 | 2023-10-24 | 사뮤메드, 엘엘씨 | 인다졸-3-카복사마이드를 사용하는 방법 및 wnt/b-카테닌 신호전달 경로 억제제로서의 그들의 용도 |
KR102558716B1 (ko) | 2016-11-07 | 2023-07-21 | 사뮤메드, 엘엘씨 | 단일-투여량, 즉시-사용가능한 주사용 제제 |
MA54133B1 (fr) | 2018-03-08 | 2022-01-31 | Incyte Corp | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y |
WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
CN108776113A (zh) * | 2018-06-06 | 2018-11-09 | 南华大学 | 一种双核铀酰配合物在atp分析中的应用 |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
US11288250B2 (en) * | 2018-08-09 | 2022-03-29 | Servicenow, Inc. | Partial discovery of cloud-based resources |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4313755A (en) | 1980-07-21 | 1982-02-02 | Shell Oil Company | N-Cyclopyopyl-N-(fluorophenyl)-N-acylureas and their herbidical use |
US4299778A (en) | 1980-07-21 | 1981-11-10 | Shell Oil Company | N'Cyclopropyl-N-(fluorophenyl)-N-hydroxyureas |
US4619686A (en) | 1984-07-17 | 1986-10-28 | Eli Lilly And Company | Pyridazinylurea compounds and methods of use as herbicides |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5451596A (en) | 1992-12-29 | 1995-09-19 | Rhone Poulenc Rorer Pharmaceuticals Inc. | Cycloalkyl amine bis-aryl squalene synthase inhibitors |
FR2707295A1 (fr) | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
DE69525418T2 (de) | 1994-05-31 | 2002-10-17 | Mitsui Chemicals Inc | Benzimidazol-derivate |
CA2193725A1 (en) | 1994-06-24 | 1996-01-04 | David Cavalla | Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity |
DK0813525T3 (da) | 1995-03-10 | 2004-02-16 | Berlex Lab | Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
CA2250204A1 (en) | 1996-04-03 | 1997-10-09 | Neville J. Anthony | Inhibitors of farnesyl-protein transferase |
US5874452A (en) | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
CA2256609C (en) | 1996-05-30 | 2005-07-26 | F. Hoffmann-La Roche Ag | 5-aroylpyrrol-2-ylmethylarene derivatives as inhibitors of prostaglandin g/h synthase |
ID24372A (id) | 1997-10-27 | 2000-07-13 | Agouron Pharma | SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs |
WO1999046244A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
CA2326804C (en) | 1998-03-31 | 2006-05-02 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
KR100605140B1 (ko) | 1998-05-22 | 2006-07-28 | 싸이오스 인크 | 심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법 |
AU3127900A (en) | 1998-12-23 | 2000-07-31 | Du Pont Pharmaceuticals Company | Thrombin or factor xa inhibitors |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
WO2000059902A2 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | Aryl sulfonyls as factor xa inhibitors |
ID30460A (id) | 1999-04-15 | 2001-12-06 | Bristol Myers Squibb Co | Inhibitor-inhibitor protein siklik tirosin kinase |
EP1177187B1 (en) | 1999-04-28 | 2007-07-25 | Sanofi-Aventis Deutschland GmbH | Di-aryl acid derivatives as ppar receptor ligands |
DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
CN1168727C (zh) | 1999-06-23 | 2004-09-29 | 阿文蒂斯药物德国有限公司 | 取代的苯并咪唑 |
FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
MX228790B (es) | 1999-09-17 | 2005-06-30 | Millennium Pharm Inc | Inhibidores del factor xa. |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
NZ517829A (en) | 1999-09-17 | 2004-12-24 | Millennium Pharm Inc | Benzamides and related inhibitors of factor Xa |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
KR20010111298A (ko) | 2000-02-05 | 2001-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | Erk의 억제제로서 유용한 피라졸 조성물 |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
WO2001068585A1 (fr) | 2000-03-14 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Nouveaux composes amides |
IL151946A0 (en) | 2000-03-29 | 2003-04-10 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
JP2004501083A (ja) * | 2000-04-18 | 2004-01-15 | アゴーロン・ファーマシューティカルズ・インコーポレイテッド | プロテインキナーゼを阻害するためのピラゾール |
ATE287886T1 (de) | 2000-04-25 | 2005-02-15 | Bristol Myers Squibb Co | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer |
US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
JP2004501913A (ja) | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | ヘテロアリール−フェニル置換Xa因子阻害剤 |
CA2410393A1 (en) | 2000-06-23 | 2002-01-03 | Dupont Pharmaceuticals Company | 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
CA2420164A1 (en) | 2000-10-20 | 2002-05-02 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
US6653301B2 (en) | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
DE10108480A1 (de) | 2001-02-22 | 2002-09-05 | Bayer Ag | Pyrazolylpyrimidine |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
WO2002072549A1 (en) | 2001-03-12 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
ATE445400T1 (de) | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
ES2247356T3 (es) | 2001-06-29 | 2006-03-01 | Cv Therapeutics, Inc. | Derivados de purina com antagonistas del receptor a2b de adenosina. |
US7064215B2 (en) | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
WO2003006465A1 (en) | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
MXPA04003954A (es) * | 2001-10-26 | 2004-11-29 | Aventis Pharma Inc | Bencimidazoles. |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
EP1460067A4 (en) | 2001-11-26 | 2005-12-07 | Takeda Pharmaceutical | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCTION OF THE DERIVATIVE, AND USE THEREOF |
WO2003053941A2 (en) | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
MXPA04007697A (es) | 2002-02-06 | 2004-11-10 | Vertex Pharma | Compuestos de heteroarilo utiles como inhibidores de gsk-3. |
WO2004041277A1 (en) | 2002-11-01 | 2004-05-21 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
BR0317003A (pt) | 2002-12-04 | 2005-10-25 | Aventis Pharma Gmbh | Derivados de imidazol como inibidores do fator xa |
CA2508681A1 (en) | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Quinoline compounds for use in mch receptor related disorders |
US20060084682A1 (en) | 2002-12-13 | 2006-04-20 | Heerding Dirk A | Thrombopoietin mimetics |
JP4585448B2 (ja) | 2002-12-23 | 2010-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 第Xa因子阻害剤としてのピラゾール−誘導体 |
US20040242559A1 (en) | 2003-04-25 | 2004-12-02 | Aventis Pharma S.A. | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors |
GB0315657D0 (en) | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
WO2005085209A1 (ja) | 2004-03-10 | 2005-09-15 | Kureha Corporation | アミン系塩基性化合物とその用途 |
EP2942349A1 (en) | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
EP1833819A1 (en) | 2004-12-30 | 2007-09-19 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
JP2008526721A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Cdk、gsk及びオーロラキナーゼの活性を調節するチアゾールおよびイソチアゾール誘導体 |
WO2006094209A2 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-benzimidazolylalkyl-substituted amide sirtuin modulators |
CA2599987A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
WO2006092430A1 (de) | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
WO2006124780A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
US7700620B2 (en) | 2005-06-27 | 2010-04-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
AU2006278505B2 (en) | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
JP2007045752A (ja) | 2005-08-10 | 2007-02-22 | Takeda Chem Ind Ltd | 5員芳香族複素環誘導体、その製造法および用途 |
DE102005057894A1 (de) | 2005-12-02 | 2007-06-06 | Basf Ag | Stabilisierte polymerisierbare Mischungen |
JP5474354B2 (ja) | 2005-12-30 | 2014-04-16 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
EP2049119A2 (en) | 2006-06-29 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea |
WO2008001101A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
-
2005
- 2005-12-30 EP EP05823721A patent/EP1833819A1/en not_active Withdrawn
- 2005-12-30 NZ NZ555982A patent/NZ555982A/en not_active IP Right Cessation
- 2005-12-30 WO PCT/GB2005/005097 patent/WO2006070195A1/en active Application Filing
- 2005-12-30 RU RU2007128959/04A patent/RU2416610C2/ru not_active IP Right Cessation
- 2005-12-30 JP JP2007548898A patent/JP5507049B2/ja not_active Expired - Fee Related
- 2005-12-30 BR BRPI0519759-7A patent/BRPI0519759A2/pt not_active IP Right Cessation
- 2005-12-30 AU AU2005321091A patent/AU2005321091B2/en not_active Ceased
- 2005-12-30 EP EP11180160A patent/EP2395000A1/en not_active Withdrawn
- 2005-12-30 CA CA2593993A patent/CA2593993C/en not_active Expired - Fee Related
- 2005-12-30 KR KR1020077017527A patent/KR101334511B1/ko not_active IP Right Cessation
- 2005-12-30 MX MX2007008008A patent/MX2007008008A/es active IP Right Grant
- 2005-12-30 US US11/813,031 patent/US8110573B2/en not_active Expired - Fee Related
- 2005-12-30 TW TW094147642A patent/TWI427077B/zh not_active IP Right Cessation
-
2007
- 2007-06-07 IL IL183751A patent/IL183751A0/en unknown
- 2007-07-26 NO NO20073926A patent/NO20073926L/no not_active Application Discontinuation
-
2011
- 2011-12-19 US US13/329,952 patent/US8778936B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2006070195A8 (en) | 2006-08-24 |
US20120190673A1 (en) | 2012-07-26 |
MX2007008008A (es) | 2007-11-12 |
JP5507049B2 (ja) | 2014-05-28 |
IL183751A0 (en) | 2007-09-20 |
CA2593993A1 (en) | 2006-07-06 |
KR20070094639A (ko) | 2007-09-20 |
WO2006070195A1 (en) | 2006-07-06 |
AU2005321091B2 (en) | 2012-04-12 |
RU2416610C2 (ru) | 2011-04-20 |
TWI427077B (zh) | 2014-02-21 |
NO20073926L (no) | 2007-10-01 |
TW200635918A (en) | 2006-10-16 |
US20080132495A1 (en) | 2008-06-05 |
CA2593993C (en) | 2014-07-29 |
RU2007128959A (ru) | 2009-02-10 |
KR101334511B1 (ko) | 2013-11-29 |
EP1833819A1 (en) | 2007-09-19 |
AU2005321091A1 (en) | 2006-07-06 |
EP2395000A1 (en) | 2011-12-14 |
US8110573B2 (en) | 2012-02-07 |
NZ555982A (en) | 2011-01-28 |
US8778936B2 (en) | 2014-07-15 |
JP2008526722A (ja) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0519759A2 (pt) | composiÇÕes farmacÊuticas | |
NO20074634L (no) | Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer | |
PT1254138E (pt) | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf | |
BRPI0517945A (pt) | derivados de quinuclidina e seu uso como antagonistas de receptor muscarìnico m3 | |
BRPI0514289A (pt) | compostos orgánicos | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
BRPI0611620A2 (pt) | mimÉticos de glicocorticàide, mÉtodos de fazÊ-los, composiÇÕes farmacÊuticas e usos dos mesmos | |
NO20055688L (no) | Organiske forbindelser | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BRPI0606317A2 (pt) | compostos de pirazol, uso dos mesmos e composição farmacêutica | |
NO20091599L (no) | Kjemiske forbindelser | |
BRPI0609719B8 (pt) | derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 | |
BR112012010186B8 (pt) | derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos | |
BRPI0410037A (pt) | inibidores da fosfatidilinositol 3-cinase | |
EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
BRPI0507034A (pt) | compostos orgánicos | |
NO20085212L (no) | Nye pyridinanaloger | |
BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
BR112012007069A2 (pt) | derivado de fenol | |
WO2007012972A3 (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
NO20060718L (no) | Substituerte tiofoner og deres anvendelse | |
BR112021026531A2 (pt) | Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2 | |
UA87284C2 (ru) | Соединения фенилпиридилпиперазина, способ их получения и фармацевтическая композиция, которая их содержит |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |